BeNeLuxBelgiumNetherlandsLuxembourg

ActoGeniX: 20 million euros round

16.03.2007

Ghent – The Belgian biopharma start-up ActoGeniX has closed a series A financing round in the volume of a20 million. The transaction was co-led by the two renowned VC investors Life Sciences Partners and GIMV. ActoGeniX has already announced a first closing of this transaction, raising a11.5 million. The company, which was founded in summer 2006, is developing a portfolio of novel therapeutic products addressing major diseases with unmet medical need, including gastrointestinal diseases, auto-immunity, allergy and metabolic diseases. ActoGeniX’ initial focus is on inflammatory bowel diseases and its lead product AG011 has been successfully tested in a clinical trial with Crohn’s disease patients. The company’s technology provides a solution to deliver active biologicals locally in the gastrointestinal tract, leading to a direct effect on target receptors present in the gut.

BeNeLuxBelgiumNetherlandsLuxembourg

12.06.2011

Brussels – Belgian specialist for regenerative medicine TiGenix NV has raised EUR15.2m through the sale of 15.2 million shares at EUR1/share in a rights issue. Existing shareholders, who were eligible to purchase one share for...

BeNeLuxBelgiumNetherlandsLuxembourg

12.06.2011

Mechelen – Belgian drug discovery specialist Galapagos NV has sold its compound business to competitor Evotec AG. The German drug-discovery services specialist thereby acquires the affiliate Compound Focus Inc., which is key to...

BeNeLuxBelgiumNetherlandsLuxembourg

12.06.2011

Amsterdam – European life sciences investor Life Sciences Partners (LSP) has raised EUR36m in an IPO for its first in-house fund to invest in public companies, selling 360,000 shares at EUR100/share. New shares in the fund, which...

BeNeLuxBelgiumNetherlandsLuxembourg

12.06.2011

One or zero, black or white, top or flop – digital results. Few sectors test the nerves of entrepreneurs, employees, partners and investors quite as much as biotechnology. Even if you have plenty of expertise, forecasting the...

BeNeLuxBelgiumNetherlandsLuxembourg

07.06.2011

Amsterdam – US-Dutch MolDx company Agendia N.V. has announced details of its planned IPO on NYSE Euronext in Amsterdam. The developer of microarray-based predictive diagnostics said it will issue 4,587,156 ordinary shares worth...

BeNeLuxBelgiumNetherlandsLuxembourg

31.05.2011

Amsterdam – Two studies presented at the annual conference of the European Society of Human Genetics yesterday show that common Direct-to-consumer (DTC) genetic tests give inaccurate predictions of disease risks and thus European...

BeNeLuxBelgiumNetherlandsLuxembourg

23.05.2011

Leuven – Genetically engineered poplars with less lignin grown in a field trial in Belgium deliver 81% more bio-ethanol than non-modified poplars when enzymatically digested and fermented, according to Belgian researchers headed...

BeNeLuxBelgiumNetherlandsLuxembourg

18.04.2011

Mechelen – Belgian Galapagos NV has terminated a Phase 2 study forGLP0259 in rheumatoid arthritis after an interim analysis showed the drug was not efficient. The failure affects Galapagos’ research agreement with Janssen...

BeNeLuxBelgiumNetherlandsLuxembourg

08.04.2011

Eindhoven – Researchers from Dutch imaging specialist Philips Electronics and the Eindhoven University of Technology have developed a technique that could help boost efficacy and at the same time reduce the side effects of...

BeNeLuxBelgiumNetherlandsLuxembourg

06.04.2011

Leuven – Belgian biotech TiGenix NV has agreed to merge operations with Spain-based Cellerix and raise a15m in a rights issue to expand further into regenerative medicine. TiGenix said it had agreed to combine operations though a...

Displaying results 41 to 50 out of 304

< Previous 41-50 Next >

© 2007-2016 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/4/article/actogenix-20-million-euros-round.html

Whitepaper

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • DIAMYD MEDICAL -B- (S)5.70 SEK21.54%
  • QIAGEN NV (D)23.48 EUR12.29%
  • MOBERG PHARMA (S)44.10 SEK10.25%

FLOP

  • MOLOGEN (D)1.81 EUR-11.71%
  • NICOX (F)9.62 EUR-8.29%
  • SAREUM HOLDINGS (UK)0.72 GBP-6.49%

TOP

  • PROTHENA PLC (IE)55.05 USD57.5%
  • DIAMYD MEDICAL -B- (S)5.70 SEK37.3%
  • VERNALIS (UK)44.50 GBP31.9%

FLOP

  • MOLOGEN (D)1.81 EUR-38.4%
  • SANTHERA (CH)56.20 CHF-26.9%
  • EVOCUTIS (UK)0.04 GBP-20.0%

TOP

  • KARO BIO (S)33.00 SEK1975.5%
  • NICOX (F)9.62 EUR428.6%
  • SAREUM HOLDINGS (UK)0.72 GBP213.0%

FLOP

  • BB BIOTECH (D)44.83 EUR-84.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.80 SEK-78.3%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 30.07.2016

Events

All Events

Partner-Events